Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study.

Background: Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic tr...

Descripción completa

Detalles Bibliográficos
Publicado en:BMC Medicine Vol. 20; no. 1; pp. 1 - 14
Autores principales: Liao, Lauren D., Ferrara, Assiamira, Greenberg, Mara B., Ngo, Amanda L., Feng, Juanran, Zhang, Zhenhua, Bradshaw, Patrick T., Hubbard, Alan E., Zhu, Yeyi
Formato: research Journal Article
Publicado: BioMed Central 9/15/2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159100541&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 159100541
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17417015
        1CI2
      jtl: BMC Medicine
      issn: 17417015
      maglogo: N
    pubinfo:
      dt: 9/15/2022
      vid: 20
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        159100541
        159100541
        NLM36104698
        159100541
        10.1186/s12916-022-02499-7
        NLM36104698
        159100541
      ppf: 1
      ppct: 13
      formats:
      tig:
        atl: Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study.
      aug:
        au:
          Liao, Lauren D.
          Ferrara, Assiamira
          Greenberg, Mara B.
          Ngo, Amanda L.
          Feng, Juanran
          Zhang, Zhenhua
          Bradshaw, Patrick T.
          Hubbard, Alan E.
          Zhu, Yeyi
        affil: Division of Biostatistics, School of Public Health, University of California, Berkeley, CA, USA
      sug:
        subj:
          Diabetes Mellitus, Gestational Diagnosis
          Diabetes Mellitus, Gestational Drug Therapy
          Female
          Hypoglycemic Agents Therapeutic Use
          Pregnancy
          Prospective Studies
          Blood Glucose
          Insulin Therapeutic Use
          Short Portable Mental Status Questionnaire
          Clinical Assessment Tools
          Impact of Events Scale
          Scales
          Female
      ab: Background: Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic treatment (antidiabetic oral agents and/or insulin)]. We investigated whether clinical data at varied stages of pregnancy can predict GDM treatment modality.Methods: Among a population-based cohort of 30,474 pregnancies with GDM delivered at Kaiser Permanente Northern California in 2007-2017, we selected those in 2007-2016 as the discovery set and 2017 as the temporal/future validation set. Potential predictors were extracted from electronic health records at different timepoints (levels 1-4): (1) 1-year preconception to the last menstrual period, (2) the last menstrual period to GDM diagnosis, (3) at GDM diagnosis, and (4) 1 week after GDM diagnosis. We compared transparent and ensemble machine learning prediction methods, including least absolute shrinkage and selection operator (LASSO) regression and super learner, containing classification and regression tree, LASSO regression, random forest, and extreme gradient boosting algorithms, to predict risks for pharmacologic treatment beyond MNT.Results: The super learner using levels 1-4 predictors had higher predictability [tenfold cross-validated C-statistic in discovery/validation set: 0.934 (95% CI: 0.931-0.936)/0.815 (0.800-0.829)], compared to levels 1, 1-2, and 1-3 (discovery/validation set C-statistic: 0.683-0.869/0.634-0.754). A simpler, more interpretable model, including timing of GDM diagnosis, diagnostic fasting glucose value, and the status and frequency of glycemic control at fasting during one-week post diagnosis, was developed using tenfold cross-validated logistic regression based on super learner-selected predictors. This model compared to the super learner had only a modest reduction in predictability [discovery/validation set C-statistic: 0.825 (0.820-0.830)/0.798 (95% CI: 0.783-0.813)].Conclusions: Clinical data demonstrated reasonably high predictability for GDM treatment modality at the time of GDM diagnosis and high predictability at 1-week post GDM diagnosis. These population-based, clinically oriented models may support algorithm-based risk-stratification for treatment modality, inform timely treatment, and catalyze more effective management of GDM.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N